Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase Two)

Purpose

This study is being done to further examine and improve how a brief clinical treatment intervention may reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.

The length of the study is approximately 10 weeks and will include two on-campus lab visits at Ohio State's Medical Campus, daily surveys via a smartphone app (surveys 3 times a day for ~21 days), three treatment sessions (completed online or in-person), and follow-up questionnaires (completed online). The total time commitment of the study is 11 hours and 6 minutes.

Could this study be right for you?

Inclusion Criteria:

• engaged in MOUD treatment (for at least one month)
• alcohol consumption (within the past 12 months)
• age 18 or older
• access to a smart phone

(partial list of inclusion criteria)

Exclusion Criteria:

• diagnosis of psychosis or bipolar I
• currently pregnant (positive pregnancy test)

(partial list of exclusion criteria)

Age Range

18 years and up

Official Title Brief Digitally Enhanced Intervention for Managing Emotional Pain and Reducing Alcohol Use during Medication for OUD (Phase One)

Purpose

This study is being done to adapt and improve a brief clinical treatment intervention that aims to reduce alcohol use among patients engaged in medication for opioid use disorder (MOUD) treatment.

The length of the study is approximately 4 weeks and will include an initial study visit, daily surveys via a smartphone app (surveys 5 times a day for ~21 days), and three treatment sessions. All study sessions can be completed online or in-person. The total time commitment of the study is 8 hours and 30 minutes.

Could this study be right for you?

Inclusion Criteria:

• engaged in MOUD treatment (for at least one month)
• alcohol consumption (within the past 12 months)
• age 18 or older
• access to a smart phone

(partial list of inclusion criteria)

Age Range

18 years and up

Official Title Establishing Reference Values and Clinical Decision Points for Quantitative Videofluoroscopic Measures of Swallowing

Purpose

This study will help create healthy reference values clinicians can use to evaluate adult patients of all ages and is sponsored by the National Institute on Aging.  During this study, we will perform an x-ray swallowing exam and breathing tests with persons who do not have a personal history of swallowing problems or any disorders that could contribute to a swallowing problem.  Study participation will consist of a screening meeting (approximately 15 minutes) via phone call, video chat, or email to verify eligibility, and one in-person visit to our laboratory (approximately 1 hour).

Could this study be right for you?

• If you are biologically female and of child-bearing age (<63), you must not be pregnant or breastfeeding.
• No personal history of surgery or radiation therapy to the head or neck (mouth, jaw, neck, brain, nose, face, thyroid, throat, or voice box) other than having your tonsils, adenoids, or teeth removed.
• No personal history of cancer involving structures of the head, neck, spine, respiratory, or lymphatic system.
• No personal history of stroke or other progressive nerve disease.
• No current diagnosis or personal history of Chronic Obstructive Pulmonary Disease (COPD).
• No known allergies to barium.

Age Range

54 - 89 years

Official Title The Development of Semantic Organization

Purpose

We are currently in the process of conducting a 5-year National Institutes of Health-funded longitudinal study on semantic and language development, specifically focusing on how children learn new words and understand their meanings. Our goal is to not only examine language learning but also how these processes evolve as children grow.

In this study, we will follow two hundred 4-year-old junior scientists as they participate in fun, interactive word-learning and language activities. Over the course of the study, participants will visit our lab twice a year, each lasting around 60-90 minutes (including breaks), to engage in a series of playful games with a research assistant designed to explore how children comprehend and retain new vocabulary. Additionally, your child will have the opportunity to wear a LENA recorder—a small, wearable device that tracks the number of words your child hears throughout the day, similar to a Fitbit but for words!

 

Could this study be right for you?

• Child must be monolingual
• Not born premature
• No developmental delays
• Can give a verbal response
• Normal to corrected vision

Age Range

4 - 4 years

Official Title Neural Biomarkers of Sensory Symptoms in Autism

Purpose

The purpose of this study is to understand sensory processing in children on the autism spectrum, Using EEG, we will look at brainwaves while children play different computer games. We will also have children play some paper-pencil games during their visit to our lab. We hope to better understand sensory experiences and support autistic people in ways that celebrate their unique strengths.

Could this study be right for you?

Inclusion criteria for the autism group are

• Diagnosis of autism from a licensed psychologist based on the Autism Diagnostic Interview-Revised or the Autism Diagnostic Observation Schedule (ADOS),
• Aged 8 - 12 years old
• Normal/corrected vision/hearing, and IQ > 65. 19 Children taking stimulant medications will be included in the study but will be required to be off medication for 24 (for short-acting preparations) to 48 h (long-acting preparations) prior to the visit 

Inclusion criteria for the age-matched TD control group include:

• No concerns/diagnoses of any neurodevelopmental, learning, or mental health conditions 

Age Range

8 - 12 years

Official Title A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)

Purpose

You are being invited to participate in a study about mesial temporal lobe epilepsy (MTLE) on only 1 side (unilateral) of the brain that has not responded to medication (refractory).

The study will test AMT-260, which is a new gene therapy under investigation for use in treating people like you with MTLE. It is not yet approved as a drug for treating MTLE. It can only be used in a study like this one. This is the first time this gene therapy will be used in humans. It has previously been studied in animals.

AMT-260 is a gene therapy designed to reduce the electrical signals between nerve cells (neurons) in the parts of your brain where nerve cells are abnormally connected. This reduces the extra electrical signals that happen at the same time and is intended to reduce your seizure activity.

The overall goals of this study are:

• To observe whether participants have any side effects from AMT-260 or from the procedure to deliver AMT-260 into the brain and how well participants tolerate any side effects that may occur.
• To measure if participants have changes in:
  • frequency of their seizures
  • how their seizures affect their life
  • how the human body takes up and removes AMT-260
• To find the best dose of AMT-260 for future participants to ensure clinical benefit with minimal or no side effects.

Could this study be right for you?

Adult, 18-65 years of age, inclusive, capable of giving informed consent.
Written informed consent is given freely after the nature of the study has been explained to the participant and the completion of data disclosure.
Willingness to undergo necessary surgical procedures.
Diagnosis of unilateral refractory MTLE for ≥360 days, confirmed by an Epilepsy Monitoring Unit.

Additional Eligibility Criteria to be assessed by neurosurgery team, and as described in the study protocol.

Age Range

18 - 65 years

Official Title IMPROVE-AD Trial: IMPRoving Outcomes in Vascular DisEase – Aortic Dissection

Purpose

The goal of this study is to figure out the best way to treat type aortic dissection. An aortic dissection is a tear in the wall of the aorta. The aorta is a big blood vessel that carries blood from your heart to the rest of your body. Individuals with this problem usually get medicine or a special repair procedure. This procedure is called thoracic endovascular aortic repair (TEVAR). TEVAR is a procedure where a metal tube (called a stent), is inserted in the damaged part of the aorta. The study is being done to figure out which treatment works better. The results of the study may help to prevent future problems with the aorta or other health issues. 

 

Could this study be right for you?

Inclusion:

• Age > 21 years
• Stanford type B aortic dissection not involving the aorta at or proximal to the innominate artery, without rupture and/or malperfusion (renal, mesenteric, or extremity)
• Acuity: within 48 hours – 6 weeks of index admission

Exclusion criteria:

• Ongoing systemic infection
• Pregnant or planning to become pregnant in the next 3 months
• Life expectancy related to non-aortic conditions < 2 years
• Prior surgery for aortic dissection

Age Range

21 years and up

Official Title AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion

Purpose

The purpose of this research is to determine if the IMPEDE-FX RapidFill System is safe and helps to shrink abdominal aortic aneurysm (AAA - a bulge or swelling due to weakening of the walls of the aorta, which is the main blood vessel that carries blood from your heart to other parts of your body) sacs after an endovascular stent graft (a fabric tube supported by metal wire stents that reinforces a weakened aorta) has been placed. The IMPEDE-FX RapidFill System used in this study is classified as investigational, which means it has not been approved by the Food and Drug Administration (FDA).

Could this study be right for you?

Inclusion:

• A candidate for elective EVAR of an infrarenal fusiform aortic aneurysm ≥5.5 cm in diameter in men and ≥ 5.0 cm in women 
• Thrombus burden (percentage of the AAA sac occupied by thrombus) <50%, based on pre-procedure CTA
• Maximum Lumen diameter within the AAA sac of ≥40mm
• The predicted minimum number of IMPEDE-FX RapidFill Implants for the subject is ≤200

Exclusion:

• An inability to provide informed consent
• Enrolled in another clinical study that could interfere with the outcomes being studied in this trial
• Unable or unwilling to comply with study follow-up requirements

Inclusion and Exclusion Criteria varies, please contact Study Coordinator for more information. 

Age Range

18 years and up

Official Title Testing Equivalence of Measures of Parental Socialization Beliefs and Behaviors Across Racial/Ethnic Groups

Purpose

This study aims to investigate the similarity and differences in parents' beliefs and practices across racial/ethnic backgrounds.

Could this study be right for you?

Eligibility Criteria includes:

• Must be proficient in written English
• You are parents of a child aged 3 to 10, who was born in the U.S.

Age Range

18 - 80 years

Official Title Operating Microscope versus Traditional Loupes during Regeneration Therapy for Peri-implantitis: A Randomized Controlled Trial with Ultrasonographic and Biomarkers Evaluation

Purpose

The purpose of this study is to compare the one-year outcomes of treating peri-implantitis with periodontal surgical means between the use of an Operating Microscope and dental loupes.

This study includes the comparisons of the changes of inflammation of the gums, the bacteria present, and wound healing at the surgical site between the two methods. The hypothesis is that the use of the operating microscope, compared to dental loupes, is associated with better bacteria removal, quicker inflammatory resolution, and improved wound healing, which will contribute to better outcomes.

Could this study be right for you?

Inclusion criteria: Participant has at least one implant indicated for peri-implant regenerative treatment.

Exclusion criteria: Participant has known systemic conditions and medication interactions that can affect healing of the surgical site.

Age Range

18 - 99 years